Welcome to our dedicated page for Becton, Dickinson and Co. news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton, Dickinson and Co. stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology firm committed to advancing healthcare through the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. Established in 1897, BD's mission is to enhance medical discovery, diagnostics, and care delivery. The company's extensive product portfolio serves healthcare institutions, physicians, life science researchers, and others across the globe.
BD is noted for being the world’s largest manufacturer and distributor of medical surgical products such as needles, syringes, and sharps-disposal units. The company also excels in producing pre-filled devices, diagnostic instruments, and reagents. Furthermore, BD offers sophisticated flow cytometry and cell-imaging systems. BD Medical represents nearly half of the company's total business, while BD Life Sciences and BD Interventional contribute 27% and 24% of the 2023 revenue, respectively. Impressively, international revenue accounts for 43% of the company's business.
Recent achievements and projects underscore BD's commitment to innovation and sustainability. The company recently collaborated with health care institutions in Denmark to explore recycling used blood collection tubes, achieving significant environmental advancements without compromising safety or quality.
In a pivotal development, BD announced the global commercial release of new cell sorters, enabling researchers in fields such as cell biology, cancer research, and immunology to gain new insights. The BD FACSDiscover™ S8 Cell Sorters incorporate groundbreaking technologies like BD CellView™ Image Technology and BD SpectralFX™ Technology, significantly enhancing real-time imaging and spectral flow cytometry.
BD also reported robust financial performance for the second quarter of fiscal 2024, highlighting strong operating margins and cash flow. This success led to an optimistic outlook and an increased earnings guidance, demonstrating the company’s resilience and strategic execution.
Further solidifying its market position, BD is set to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion. This acquisition expands BD’s portfolio in smart connected care solutions, leveraging advanced AI algorithms for better patient outcomes and adding significant value to its operations.
With a presence in almost every country and a workforce of over 70,000 employees, BD remains dedicated to advancing the world of health. The company works closely with customers and partners globally to address complex health challenges, enhance clinical outcomes, and expand access to healthcare.
BD (Becton, Dickinson and Company) announced that the new name for its upcoming spinoff of the Diabetes Care business will be embecta. This independent, publicly-traded company aims to empower those living with diabetes while maintaining a connection to BD's legacy. The spinoff is expected to finalize in the second quarter of 2022. Devdatt Kurdikar will serve as CEO, leading a diverse team focused on innovation and improvement in diabetes care products. The name reflects the company's commitment and heritage, aiming to enhance the quality of life for diabetes patients globally.
BD (Becton, Dickinson and Company) has acquired Venclose, Inc., a leader in treatments for chronic venous insufficiency (CVI). This acquisition enhances BD's portfolio of venous disease technologies, leveraging Venclose's innovative Radio Frequency (RF) ablation system that is designed for efficiency and versatility. CVI affects up to 40% of women and 17% of men in the U.S. The dual heating length of the Venclose System allows multiple vein segments to be ablated with one catheter, potentially reducing post-operative pain for patients. The financial impact of the deal is expected to be immaterial for BD's fiscal 2022.
BD (Becton, Dickinson and Company) (NYSE: BDX) issued a statement confirming the effectiveness of its rapid antigen and PCR tests for detecting the COVID-19 Omicron variant. Conducting an analysis based on genome sequences up to Nov. 29, 2021, BD remains confident that its testing methods will identify this new variant. To date, the company has evaluated over 3.5 million SARS-CoV-2 genomes and reported no undetectable variants. BD emphasizes the importance of reliable testing in combating COVID-19's spread and will continue rigorous performance monitoring.
BD (Becton, Dickinson and Company) has appointed Dr. Joseph M. Smith as the new senior vice president and chief scientific officer, effective November 29, 2021. In this role, Smith will oversee external innovation and the technology roadmap for BD, focusing on the future of healthcare, including smart connected care and chronic disease management. He has over 30 years of experience in digital health, previously serving as CEO of Digital Health Corp. Smith holds multiple advanced degrees and has authored numerous publications while holding several patents.
BD (Becton, Dickinson and Company) has appointed Francesca DeMartino as senior vice president of investor relations, effective Nov. 29. DeMartino will oversee the communication of the BD2025 strategy to investors, focusing on shareholder value. She brings over 20 years of experience in investor relations from notable companies, including Medtronic, where her team won awards for investor relations. DeMartino succeeds Kristen Stewart, who moves to a new role within the company.
BD (Becton, Dickinson and Company) hosted its Investor Day on Nov. 12, 2021, focusing on its BD 2025 strategy to drive growth through innovation and operational simplification. The company aims for a long-term compound annual revenue growth of 5.5% or more, with double-digit EPS growth and increasing dividends. Key initiatives include organic and inorganic investments, reshaping the innovation pipeline with higher-margin products, and enhancing margins through simplification programs. BD emphasizes disciplined capital deployment to balance growth investments and shareholder returns.
QIAGEN N.V. (NYSE: QGEN) and Becton, Dickinson and Company (NYSE: BDX) have settled a patent infringement lawsuit concerning QIAGEN’s NeuMoDx™ PCR systems. The settlement, resolving all claims, mandates a one-time payment of
BD (Becton, Dickinson and Company) reported strong fiscal 2021 results, with Q4 revenues reaching $5.135 billion, a 7.3% increase year-over-year. Diluted EPS was $0.84, up 133.3%. The company achieved revenue growth across segments, led by BD Medical's 9.2% rise. Despite a decline in COVID-19 diagnostic revenue, BD's outlook for fiscal 2022 anticipates revenue between $19.3 billion and $19.5 billion and adjusted EPS of $12.30 to $12.50, reflecting 5-6% growth. BD also increased its dividend by 4.8% and repurchased 3 million shares for $750 million.
The Board of Directors of BD (Becton, Dickinson and Company) declared a quarterly dividend of $0.87 per share, up 4.8% from the previous quarter, payable on December 31, 2021. This marks the 50th consecutive year of dividend increases, reinforcing BD's status in the S&P 500 Dividend Aristocrats Index. Additionally, the board authorized a share repurchase of up to 10 million shares, adding to the remaining 750,000 shares from a previous program. This strategic move is aimed at enhancing shareholder value, aligned with the company's 2025 strategy.
BD (Becton, Dickinson and Company) has announced a strategic partnership with the Biomedical Advanced Research and Development Authority (BARDA) to develop a suite of COVID-19 combination diagnostic tests. This collaboration will receive initial funding of $24.7 million, potentially extending to $40.3 million. The new tests aim to simultaneously detect multiple respiratory pathogens, enhancing patient management and healthcare resource allocation. BD plans to achieve full FDA clearance for these tests, ensuring their availability even post-COVID-19 emergency.
FAQ
What is the current stock price of Becton, Dickinson and Co. (BDX)?
What is the market cap of Becton, Dickinson and Co. (BDX)?
What does Becton, Dickinson and Company (BD) specialize in?
What are BD's main business segments?
What recent projects has BD undertaken?
How much of BD's revenue comes from international markets?
What significant acquisition has BD announced recently?
How many employees does BD have?
Where can I find more information about BD's financial performance?
What is the significance of the BD FACSDiscover™ S8 Cell Sorters?
Which regulatory body recently issued a safety communication regarding syringes?
What is BD's approach to sustainability?
